Cancer, Leukemia |
|
 |
|
Products: Anti-cancer drugs
Gleevec
GLEEVEC® (imatinib mesylate) is indicated for the treatment of:
-----Newly diagnosed adult patients with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in the chronic phase (CP)
-----Patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in CP after failure of interferon-alpha therapy
-----Adult patients with relapsed or refractory Ph+ acute lymphoblastic leukemia (Ph+ ALL)
-----Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements
-----Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-KIT mutation or with c-KIT mutational status unknown
-----Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase–negative or unknown
-----Adult patients with unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans (DFSP)
-----Patients with KIT (CD117)–positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST)
-----Adjuvant treatment of adult patients following resection of KIT (CD117)–positive GIST
gleevac, druker, chronic myelogenous, gastrointestinal stromal, su11248, sti571, gleevec side effects, gleevec drug, gleevec cost, gleevec resistance, gleevec diabetes - key phrases.
|
|
Cancer, Leukemia
|
|
My Basket